Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Top Cited Papers
- 2 December 2008
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (48) , 18895-18900
- https://doi.org/10.1073/pnas.0810246105
Abstract
The recent development of small-molecule tyrosine kinase (TK) inhibitors offers increasing opportunities for the treatment of autoimmune diseases. In this study, we investigated the potential of this new class of drugs to treat and cure type 1 diabetes (T1D) in the NOD mouse. Treatment of prediabetic and new onset diabetic mice with imatinib (Gleevec) prevented and reversed T1D. Similar results were observed with sunitinib (Sutent), an additional approved multikinase inhibitor, suggesting that the primary target of imatinib, c-Abl, was not essential in blocking disease in this model. Additional studies with another TK inhibitor, PLX647 (targeting c-Kit and c-Fms) or an anti-c-Kit mAb showed only marginal efficacy whereas a soluble form of platelet-derived growth factor receptor (PDGFR), PDGFRβIg, rapidly reversed diabetes. These findings strongly suggest that inhibition of PDGFR is critical to reverse diabetes and highlight a crucial role of inflammation in the development of T1D. These conclusions were supported by the finding that the adaptive immune system was not significantly affected by imatinib treatment. Finally, and most significantly, imatinib treatment led to durable remission after discontinuation of therapy at 10 weeks in a majority of mice. Thus, long-term efficacy and tolerance is likely to depend on inhibiting a combination of tyrosine kinases supporting the use of selective kinase inhibitors as a new, potentially very attractive approach for the treatment of T1D.Keywords
This publication has 52 references indexed in Scilit:
- Development and dynamics of robust T-cell responses to CML under imatinib treatmentBlood, 2008
- Immunomodulatory mast cells: negative, as well as positive, regulators of immunityNature Reviews Immunology, 2008
- Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell NichesScience, 2007
- Modulation of T-effector function by imatinib at the level of cytokine secretionExperimental Hematology, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infectionsBlood, 2006
- Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritisJournal of Clinical Investigation, 2006
- Amelioration of autoimmune nephritis by imatinib in MRL/lpr miceArthritis & Rheumatism, 2005
- Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylateLeukemia, 2004
- Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemiaClinical Rheumatology, 2003